The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Semaglutide can help the body make more insulin and improves insulin sensitivity, which in turn lowers blood-glucose levels ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

Geneticist Michael Klotsman was frustrated by human drug development. That led him to launch a startup focused on treatments ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...